CD8A and neoplasm: In line with this, treatment of mice bearing the Arf1‐ablated tumor cells with anti‐IFNAR1 and anti‐IL‐1β antibodies had markedly reduced frequency of the TNF+IFNg+PD1+CD8+ T cells in tumors in comparison with those in tumors treated with the isotype control antibody (Figure 6e,f).